-- A group of independent experts from the influential peer-reviewed journal has evaluated Grifols' AMBAR results (Alzheimer Management by Albumin Replacement)
-- Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's
-- The publication reflects more than 15 years of Grifols' research and confirms the potential for plasma therapies to address high-prevalence diseases
PR Newswire
BARCELONA, Spain, July 27, 2020
